Ankush Manwati

• Currently leading the strategy and marketing for HCP channel for the INR 284Cr (€30.9m) Healthy Ageing Portfolio comprising of legacy brands like Protinex.
• Led a dynamic overhaul of our marketing strategy, reinvigorating the team with a data-driven approach that prioritized customer engagement and competitive analysis. This strategic pivot resulted in a notable & consistent surge in HCP recommendation share from 22.1% (May'22), 28.7% (May'23) to 34.9% (May'24).
• Led the successful entry into the Diabetes Nutrition category with Protinex Diabetes Care. Spearheaded the development of marketing, communication & GTM strategy and worked closely with cross functional teams for product development, distribution plan.
• Protinex Diabetes Care was able to swiftly capture market share of 7.1% (Nielsen Mat June'24) with a topline of €3.4m (L12M).

• Oversaw the HCP marketing strategy for an Adult Nutrition portfolio valued at €49.2 million, encompassing renowned brands such as Ensure and Ensure Diabetes Care (Glucerna). My role involved orchestrating targeted campaigns, fostering strong relationships with healthcare professionals, and driving brand growth through evidence-based marketing practices.

• Accomplishment: Ensure moved to #2 spot in the C&B category with 18.2% MS MAT Jan’21 (+3.4% Vs MAT Jan’20), Ensure Diabetes Care gained leadership position in the Diabetes Specific Nutrition Category with 48.8% MS, MAT Jan’21 (+12.2% Vs MAT Jan’20).

• “Strategically spearheaded the market introduction of two innovative hematinic brands, Jilazo (Iron Isomaltoside) and Lupiheme (Heme Iron Polypeptide), targeting untapped opportunities in Gastroenterology and Patient Blood Management.
• Oversaw a Hematinic portfolio with a robust revenue of $5.1 million, successfully steering Lupiheme to achieve a 2.4% market share and attain the 5th rank in its category within the first year post-launch, reflecting strategic market penetration and effective brand positioning.

Promoted a comprehensive range of vaccines to pediatricians in the Bangalore market. My dedicated efforts and strategic approach led to consecutively securing the 2nd highest sales across country in both 2010 and 2011, demonstrating exceptional sales acumen and product advocacy.”

I was part of the Nephrology and Oncology division, promoting Erythropoietin (Dialysis) and Immunosuppressants (Kidney Transplant) in the nephrology segment. Was part of the successful launch of a new oncology portfolio, which expanded treatment options and reinforced the company’s commitment to innovative healthcare solutions.”